{
    "clinical_study": {
        "@rank": "8411", 
        "arm_group": [
            {
                "arm_group_label": "Group HRV Liq", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive two doses of Liquid Human Rotavirus Vaccine according to a 0, 1 month schedule."
            }, 
            {
                "arm_group_label": "Group HRV Lyo", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive two doses of Lyophilized Human Rotavirus Vaccine according to a 0, 1 month schedule."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate and compare immunogenicity, reactogenicity and\n      safety of two formulations (liquid vs. lyophilised) of GSK Biologicals' HRV vaccine when\n      administered as two doses in healthy infants aged \u2265 6 weeks."
        }, 
        "brief_title": "Immunogenicity and Safety Study of Two Different Formulations of Human Rotavirus Vaccine, Rotarix in Healthy Infants", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Rotavirus", 
        "condition_browse": {
            "mesh_term": "Rotavirus Infections"
        }, 
        "detailed_description": {
            "textblock": "This protocol summary has been amended based on NDAC- Vaccines (New Drug Advisory Committee\n      on Vaccines) of Drugs Controller General of India (DCGI)'s recommendation to conduct this\n      study as a Phase IV study instead of phase III, because the Rotarix liquid file application\n      is considered as a line extension of Rotarix Lyophilized formulation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable\n             Representative(s) can and will comply with the requirements of the protocol.\n\n          -  A male or female between, and including, 6 and 10 weeks of age at the time of the\n             first vaccination.\n\n          -  Written informed consent obtained from the parent(s)/ Legally Acceptable\n             Representative(s) of the subject.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Birth weight >2000 g.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine, or planned use during the\n             study period.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs since\n             birth. Inhaled and topical steroids are allowed.\n\n          -  Administration of any chronic drug therapy to be continued during the study period.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             within 30 days of the first dose of study vaccine with the exception for the routine\n             childhood vaccinations.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational product.\n\n          -  History of confirmed RV GE.\n\n          -  Previous vaccination against RV.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, (including\n             Severe Combined Immunodeficiency disorder) based on medical history and physical\n             examination.\n\n          -  Uncorrected congenital malformation (such as Meckel's diverticulum) of the\n             gastrointestinal tract that would predispose for Intussusception or history of\n             Intussusception.\n\n          -  Family history of congenital or hereditary immunodeficiency.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccine.\n\n          -  Major congenital defects or serious chronic illness.\n\n          -  History of any neurological disorders or seizures.\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C /99.5\u00b0F on oral, axillary or tympanic\n                  setting, or \u2265 38.0\u00b0C /100.4\u00b0F on rectal setting. The preferred route for\n                  recording temperature in this study will be axillary.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator\n                  (warrants deferral of the vaccination).\n\n          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal\n             functional abnormality, as determined by physical examination or medical history.\n\n          -  Administration of immunoglobulins and/or any blood products since birth or planned\n             administration during the study period.\n\n          -  GE within 7 days preceding the study vaccine administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "10 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "308", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141204", 
            "org_study_id": "116566", 
            "secondary_id": "2012-001875-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group HRV Liq", 
                "description": "Oral administration", 
                "intervention_name": "Liquid Human Rotavirus Vaccine 444563", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group HRV Lyo", 
                "description": "Oral administration", 
                "intervention_name": "Lyophilized Human Rotavirus Vaccine 444563", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HRV", 
            "Liquid vaccine", 
            "Human rotavirus vaccine"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Anti-rotavirus antibody seroconversion rate.", 
            "safety_issue": "No", 
            "time_frame": "One month after Dose 2 of HRV lyophilized vaccine and HRV liquid vaccine."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141204"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anti-rotavirus antibody concentrations in terms of Geometric Mean Concentrations (GMCs).", 
                "safety_issue": "No", 
                "time_frame": "One month after Dose 2 of HRV lyophilized vaccine and HRV liquid vaccine."
            }, 
            {
                "measure": "Occurrence of  solicited adverse events.", 
                "safety_issue": "No", 
                "time_frame": "Within the 8-day (Day 0 - Day 7) solicited follow-up period after each dose of HRV lyophilized vaccine and HRV liquid vaccine."
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events.", 
                "safety_issue": "No", 
                "time_frame": "Within 31 days (Day 0 - Day 30) after any dose of HRV lyophilized vaccine and HRV liquid vaccine."
            }, 
            {
                "measure": "Occurrence of serious adverse events.", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study period (Dose 1 up to study end [Approximately 2 Months])."
            }, 
            {
                "measure": "Presence of wild type rotavirus (RV) in gastroenteritis (GE) stool samples.", 
                "safety_issue": "No", 
                "time_frame": "Stool samples collected from Visit 1 (Days 0) up to Visit 3 (Months 2)."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}